NanoViricides, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNVC research report →
Price Chart
About the company
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses.
- CEO
- Anil R. Diwan
- IPO
- 2005
- Employees
- 7
- HQ
- Shelton, CT, US
Get TickerSpark's AI analysis on NNVC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.27M
- P/E
- -3.03
- Fwd P/E
- 17.47
- PEG
- -0.06
- P/S
- 0.00
- P/B
- 3.09
- EV/EBITDA
- -3.99
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -92.69%
- ROIC
- -89.32%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-9,591,645
- Net Income
- $-9,466,966-14.1%
- EPS
- $-0.63+10.0%
- OCF Growth
- -34.3%
- FCF Growth
- -31.9%
- 52W High
- $2.23
- 52W Low
- $0.85
- 50D MA
- $1.46
- 200D MA
- $1.30
- Beta
- 1.69
- RSI (14)
- 36
- Avg Volume
- 903.10K
No earnings-call transcripts are available for NNVC yet.
- Free Float
- 83.0%
- Shares Outstanding
- 25.40M
- Float Shares
- 21.08M
of shares held by institutions
45 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NNVC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kelly LoefflerSenate · GA | Sell | Apr 7, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 605.58K | 0 |
| Bernard Wealth Management Corp. | 500 | 0 |
Held by 20 ETFs
Biggest fund positions in NNVC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 21, 17 | BONIUK MILTON | other | 0 |
| Feb 21, 17 | Stephenson Fournier, PLLC | other | 0 |
| Aug 8, 22 | Diwan Anil | other | 94,471 |
| Feb 7, 20 | Jawadakar Makarand | other | 0 |
| Jun 2, 19 | Day Mark D. | other | 0 |
| May 21, 18 | BONIUK MILTON | other | 5,500,000 |
| Feb 21, 17 | BONIUK MILTON | other | 1,746,288 |
| Jul 11, 17 | BONIUK MILTON | other | 120,744 |
| May 4, 17 | BONIUK MILTON | other | 149,478 |
| Feb 21, 17 | BONIUK MILTON | other | 153,611 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NNVC coverage
Recent articles, reports, and earnings notes.
No research on NNVC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NNVC report →The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
accessnewswire.com · Aug 18
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
accessnewswire.com · Aug 10
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
accessnewswire.com · Jul 28
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
accessnewswire.com · Jul 24
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
accessnewswire.com · Jul 13
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
accessnewswire.com · Jul 8
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
accessnewswire.com · Jul 6
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
accessnewswire.com · Jun 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.